CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 6,000 shares, an increase of 87.5% from the December 31st total of 3,200 shares. Based on an average trading volume of 14,500 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CLGN shares. D. Boral Capital restated a “buy” rating and set a $14.00 price target on shares of CollPlant Biotechnologies in a research note on Wednesday, November 27th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CollPlant Biotechnologies stock. Villere ST Denis J & Co. LLC raised its holdings in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) by 24.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 484,867 shares of the company’s stock after acquiring an additional 95,000 shares during the period. Villere ST Denis J & Co. LLC owned 4.23% of CollPlant Biotechnologies worth $2,407,000 at the end of the most recent reporting period. 21.69% of the stock is owned by institutional investors and hedge funds.

CollPlant Biotechnologies Trading Up 2.0 %

Shares of NASDAQ:CLGN traded up $0.08 during midday trading on Wednesday, hitting $3.83. 1,844 shares of the stock were exchanged, compared to its average volume of 6,796. CollPlant Biotechnologies has a twelve month low of $3.24 and a twelve month high of $6.75. The company has a 50 day moving average price of $3.95 and a 200-day moving average price of $4.38. The stock has a market cap of $43.80 million, a P/E ratio of -2.48 and a beta of 0.63.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its quarterly earnings data on Wednesday, November 27th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. During the same period last year, the company earned ($0.38) EPS. On average, equities research analysts expect that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.